NCLEX-RN Pharmacology Practice
Questions |
Introduction to Pharmacology |
20 Original NGN-Style NCLEX Nursing
Exam Questions with Rationales
Question 1
Clinical Scenario
A 45-year-old male is admitted to the medical-surgical unit with
an acute exacerbation of Crohn's disease. The healthcare
provider prescribes a new oral extended-release corticosteroid.
During the admission assessment, the patient asks the nurse,
"Why do I have to take such a large dose of this pill by mouth,
when my brother got a much smaller dose of the same type of
medicine through his IV last month?"
Question Stem
Which pharmacological principle should the nurse use to
formulate the best explanation for the patient?
A. First-pass effect B. Protein binding capacity C. Serum half-life
D. Therapeutic index
Correct Answer
,Correct Answer: A. First-pass effect
Detailed Rationale
The first-pass effect is a phenomenon of drug metabolism
whereby the concentration of a drug, specifically when
administered orally, is greatly reduced before it reaches the
systemic circulation. After a drug is swallowed, it is absorbed by
the digestive system and enters the hepatic portal system. It is
carried through the portal vein to the liver, where it may be
extensively metabolized by hepatic enzymes. Consequently,
only a fraction of the active drug escapes the liver unchanged to
exert a systemic effect. This necessitates a significantly higher
oral dose compared to an intravenous (IV) dose of the same
medication, as IV medications completely bypass the liver's
initial metabolic pass, delivering 100% of the drug directly into
the systemic circulation (bioavailability of 1.0).
Option B is incorrect because protein binding refers to the
degree to which a drug attaches to proteins within the blood
plasma, which affects its distribution and free fraction, but does
not dictate the difference between oral and IV dosing
requirements related to initial metabolism. Option C is incorrect
because serum half-life represents the time required for the
plasma concentration of a drug to decrease by 50%; it
influences dosing frequency rather than route-dependent dose
sizes. Option D is incorrect because the therapeutic index
,measures a drug's safety profile (the ratio of toxic dose to
therapeutic dose) and does not explain route-of-administration
dosing variances.
Learning Objective
After completing this question, the learner should be able to:
• Define the first-pass effect and its impact on drug
bioavailability.
• Contrast the physiological pathways of oral versus
intravenous drug administration.
• Explain why oral doses of certain medications must be
substantially higher than their intravenous counterparts.
Medication Safety Focus
Medication administration
Question 2
Clinical Scenario
An 78-year-old female with a history of severe chronic
malnutrition and stage 4 chronic kidney disease is admitted for
a deep vein thrombosis. The patient’s serum albumin level is 1.8
g/dL (normal: 3.5–5.0 g/dL). The healthcare provider prescribes
phenytoin, a highly protein-bound antiepileptic medication, for
a concurrent seizure disorder.
Question Stem
, Based on the patient's laboratory values, the nurse should
monitor the patient closely for which physiological outcome?
A. Subtherapeutic drug levels due to rapid hepatic clearance B.
Increased risk of drug toxicity due to an elevated fraction of
free, active drug C. Decreased therapeutic effect due to a lack of
available transport proteins D. Prolonged delay in the onset of
the medication's therapeutic action
Correct Answer
Correct Answer: B. Increased risk of drug toxicity due to an
elevated fraction of free, active drug
Detailed Rationale
Many medications bind reversibly to plasma proteins, primarily
albumin, as they circulate in the bloodstream. Only the
unbound, or "free," fraction of the drug is pharmacologically
active and capable of leaving the vascular space to interact with
tissue receptors, exert therapeutic effects, or undergo
metabolism and excretion. When a patient has severe
hypoalbuminemia (serum albumin of 1.8 g/dL), there are fewer
binding sites available for a highly protein-bound drug like
phenytoin. As a result, a significantly larger percentage of the
drug remains unbound and free in the plasma. This unexpected
surge in free drug molecules amplifies both the intended
therapeutic response and the risk of severe toxicity, even if the
Questions |
Introduction to Pharmacology |
20 Original NGN-Style NCLEX Nursing
Exam Questions with Rationales
Question 1
Clinical Scenario
A 45-year-old male is admitted to the medical-surgical unit with
an acute exacerbation of Crohn's disease. The healthcare
provider prescribes a new oral extended-release corticosteroid.
During the admission assessment, the patient asks the nurse,
"Why do I have to take such a large dose of this pill by mouth,
when my brother got a much smaller dose of the same type of
medicine through his IV last month?"
Question Stem
Which pharmacological principle should the nurse use to
formulate the best explanation for the patient?
A. First-pass effect B. Protein binding capacity C. Serum half-life
D. Therapeutic index
Correct Answer
,Correct Answer: A. First-pass effect
Detailed Rationale
The first-pass effect is a phenomenon of drug metabolism
whereby the concentration of a drug, specifically when
administered orally, is greatly reduced before it reaches the
systemic circulation. After a drug is swallowed, it is absorbed by
the digestive system and enters the hepatic portal system. It is
carried through the portal vein to the liver, where it may be
extensively metabolized by hepatic enzymes. Consequently,
only a fraction of the active drug escapes the liver unchanged to
exert a systemic effect. This necessitates a significantly higher
oral dose compared to an intravenous (IV) dose of the same
medication, as IV medications completely bypass the liver's
initial metabolic pass, delivering 100% of the drug directly into
the systemic circulation (bioavailability of 1.0).
Option B is incorrect because protein binding refers to the
degree to which a drug attaches to proteins within the blood
plasma, which affects its distribution and free fraction, but does
not dictate the difference between oral and IV dosing
requirements related to initial metabolism. Option C is incorrect
because serum half-life represents the time required for the
plasma concentration of a drug to decrease by 50%; it
influences dosing frequency rather than route-dependent dose
sizes. Option D is incorrect because the therapeutic index
,measures a drug's safety profile (the ratio of toxic dose to
therapeutic dose) and does not explain route-of-administration
dosing variances.
Learning Objective
After completing this question, the learner should be able to:
• Define the first-pass effect and its impact on drug
bioavailability.
• Contrast the physiological pathways of oral versus
intravenous drug administration.
• Explain why oral doses of certain medications must be
substantially higher than their intravenous counterparts.
Medication Safety Focus
Medication administration
Question 2
Clinical Scenario
An 78-year-old female with a history of severe chronic
malnutrition and stage 4 chronic kidney disease is admitted for
a deep vein thrombosis. The patient’s serum albumin level is 1.8
g/dL (normal: 3.5–5.0 g/dL). The healthcare provider prescribes
phenytoin, a highly protein-bound antiepileptic medication, for
a concurrent seizure disorder.
Question Stem
, Based on the patient's laboratory values, the nurse should
monitor the patient closely for which physiological outcome?
A. Subtherapeutic drug levels due to rapid hepatic clearance B.
Increased risk of drug toxicity due to an elevated fraction of
free, active drug C. Decreased therapeutic effect due to a lack of
available transport proteins D. Prolonged delay in the onset of
the medication's therapeutic action
Correct Answer
Correct Answer: B. Increased risk of drug toxicity due to an
elevated fraction of free, active drug
Detailed Rationale
Many medications bind reversibly to plasma proteins, primarily
albumin, as they circulate in the bloodstream. Only the
unbound, or "free," fraction of the drug is pharmacologically
active and capable of leaving the vascular space to interact with
tissue receptors, exert therapeutic effects, or undergo
metabolism and excretion. When a patient has severe
hypoalbuminemia (serum albumin of 1.8 g/dL), there are fewer
binding sites available for a highly protein-bound drug like
phenytoin. As a result, a significantly larger percentage of the
drug remains unbound and free in the plasma. This unexpected
surge in free drug molecules amplifies both the intended
therapeutic response and the risk of severe toxicity, even if the
